🚀 VC round data is live in beta, check it out!
Fulcrum Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Fulcrum Therapeutics and similar public comparables like Agomab Therapeutics, Tectonic Therapeutic, Zura Bio, Absci and more.
Fulcrum Therapeutics Overview
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Founded
2015
HQ
Employees
55
Website
Financials (LTM)
EV
$207M
Fulcrum Therapeutics Financials
Fulcrum Therapeutics reported last 12-month revenue of — and negative EBITDA of ($89M).
In the same LTM period, Fulcrum Therapeutics generated — in gross profit, ($89M) in EBITDA losses, and had net loss of ($79M).
Revenue (LTM)
Fulcrum Therapeutics P&L
In the most recent fiscal year, Fulcrum Therapeutics reported revenue of — and EBITDA of ($83M).
Fulcrum Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($89M) | XXX | ($83M) | XXX | XXX | XXX |
| Net Profit | ($79M) | XXX | ($75M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Fulcrum Therapeutics Stock Performance
Fulcrum Therapeutics has current market cap of $553M, and enterprise value of $207M.
Market Cap Evolution
Fulcrum Therapeutics' stock price is $8.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $207M | $553M | 0.0% | XXX | XXX | XXX | $-1.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFulcrum Therapeutics Valuation Multiples
Fulcrum Therapeutics trades at (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Fulcrum Therapeutics Financial Valuation Multiples
As of April 20, 2026, Fulcrum Therapeutics has market cap of $553M and EV of $207M.
Equity research analysts estimate Fulcrum Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fulcrum Therapeutics has a P/E ratio of (7.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $553M | XXX | $553M | XXX | XXX | XXX |
| EV (current) | $207M | XXX | $207M | XXX | XXX | XXX |
| EV/EBITDA | (2.3x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (2.4x) | XXX | XXX | XXX |
| P/E | (7.0x) | XXX | (7.4x) | XXX | XXX | XXX |
| EV/FCF | (3.2x) | XXX | (3.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fulcrum Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Fulcrum Therapeutics Margins & Growth Rates
Fulcrum Therapeutics' revenue in the last fiscal year declined by (100%).
Fulcrum Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
Fulcrum Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Fulcrum Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Agomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tectonic Therapeutic | XXX | XXX | XXX | XXX | XXX | XXX |
| Zura Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| Immix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fulcrum Therapeutics M&A Activity
Fulcrum Therapeutics acquired XXX companies to date.
Last acquisition by Fulcrum Therapeutics was on XXXXXXXX, XXXXX. Fulcrum Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Fulcrum Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFulcrum Therapeutics Investment Activity
Fulcrum Therapeutics invested in XXX companies to date.
Fulcrum Therapeutics made its latest investment on XXXXXXXX, XXXXX. Fulcrum Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Fulcrum Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fulcrum Therapeutics
| When was Fulcrum Therapeutics founded? | Fulcrum Therapeutics was founded in 2015. |
| Where is Fulcrum Therapeutics headquartered? | Fulcrum Therapeutics is headquartered in United States. |
| How many employees does Fulcrum Therapeutics have? | As of today, Fulcrum Therapeutics has over 55 employees. |
| Who is the CEO of Fulcrum Therapeutics? | Fulcrum Therapeutics' CEO is Alex C. Sapir. |
| Is Fulcrum Therapeutics publicly listed? | Yes, Fulcrum Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Fulcrum Therapeutics? | Fulcrum Therapeutics trades under FULC ticker. |
| When did Fulcrum Therapeutics go public? | Fulcrum Therapeutics went public in 2019. |
| Who are competitors of Fulcrum Therapeutics? | Fulcrum Therapeutics main competitors are Agomab Therapeutics, Tectonic Therapeutic, Zura Bio, Absci. |
| What is the current market cap of Fulcrum Therapeutics? | Fulcrum Therapeutics' current market cap is $553M. |
| Is Fulcrum Therapeutics profitable? | No, Fulcrum Therapeutics is not profitable. |
| What is the current EBITDA of Fulcrum Therapeutics? | Fulcrum Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Fulcrum Therapeutics? | Current EBITDA multiple of Fulcrum Therapeutics is (2.3x). |
| What is the current FCF of Fulcrum Therapeutics? | Fulcrum Therapeutics' last 12 months FCF is ($65M). |
| What is the current EV/FCF multiple of Fulcrum Therapeutics? | Current FCF multiple of Fulcrum Therapeutics is (3.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.